Oligonucleotide Characterisation Services case study

Published: 30-Oct-2012
Analysis

Intertek has more than 15 years\' experience of providing comprehensive GLP/cGMP analytical support to clients involved in oligonucleotide development and manufacturing

Intertek has more than 15 years' experience of providing comprehensive GLP/cGMP analytical support to clients involved in oligonucleotide development and manufacturing.

There is a requirement for robust and accurate analytical characterisation strategies for assessing composition and purity of these complex products (siRNA, Antisense oligonucleotide (DNA-like) or Aptamer) and starting materials. One key technique is 31P NMR and its application to structural characterisation and P containing impurities.

Download the 31P NMR Case Study.

  • Companies:
  • Intertek
See more

You may also like

Design & Build

Intertek announces new European bioanalytical facility for biologic medicines

Read more
New European immunochemistry laboratory will meet clients’ global demand for clinical development support

Trending Articles

  1. Huber Huber Kältemaschinenbau SE is the technology leader for high precision thermoregulation solutions in research and industry. Huber products ensure precise temperature control throughout the whole world in laboratories, pilot plants and production processes. Our product range offers temperature control solutions for applications from -125°C to +425°C.
  2. Biotech Fluidics AB At Biotech Fluidics, our aim is to help you make your analytical work more effective and reliable.
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Labtex Labtex is a specialist laboratory and process chemistry equipment solutions provider. A dynamic team of professionals with expertise in research and process development across a wide range of industries and disciplines.
  5. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Design & Build

Intertek announces new European bioanalytical facility for biologic medicines

New European immunochemistry laboratory will meet clients’ global demand for clinical development support
Finance

Intertek opens GMP pharmaceutical stability storage facilities

New facility is one of Europe’s largest and is located in Cambridge, UK, at the heart of Europe’s life science and healthcare cluster
Skin Care

Intertek Clinical Research Services moves to new laboratory facility

Intertek Clinical Research Services has more than doubled the size of its laboratory, enabling it to accommodate and deliver larger projects for its customers
Analysis

Intertek expert invited as lead instructor at Pittcon 2015

Sharing pharmaceutical trace analysis knowledge with industry peers
Regulatory

Intertek to launch expansion for complex pharmaceutical stability studies at CPhI/ICSE Worldwide

Stability studies provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of factors such as temperature, humidity & light
Analysis

Intertek launches unique pharma NMR spectroscopy through its accredited facility

Facility is cGMP-compliant and is available through Intertek’s existing centre of excellence for NMR spectroscopy and analytical services in Manchester, UK
Design & Build

Intertek expands San Diego immunochemistry centre of excellence

New facility will provide expanded support for Intertek’s customers in preclinical and clinical drug development
Subscribe now